Mirae Asset Global Etfs Holdings Ltd. Candel Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 12,165 shares of CADL stock, worth $107,052. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,165
Previous 10,825
12.38%
Holding current value
$107,052
Previous $75,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
77Shares Held
15.6MCall Options Held
981KPut Options Held
521K-
Baker Bros. Advisors LP New York, NY2.98MShares$26.2 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$17.1 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$17 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$14.1 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$11.8 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $254M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...